Several new agents have become available to treat renal cell cancer (RCC) in recent years, although evidence on their dissemination is limited. This study examined recent trends in RCC treatment in US community practices. Data from the population-based National Cancer Institute's Patterns of Care studies were used to evaluate treatment of patients with RCC newly diagnosed in 2004 and 2009 (N=2357). Descriptive statistics and logistic and Cox proportional hazards regression analyses were used to assess treatment patterns and the associations among demographic, clinical, and hospital characteristics, with receipt of systemic therapy and time-tosystemic treatment. Between 2004 and 2009, systemic therapy use increased among patients with stage III and IV RCC, from 3.8% to 15.7% and 35.2% to 57.4%, respectively. Among patients with stage IV disease, the most commonly used therapies changed from interleukin-2 (16.3%) and interferon-alfa (16.6%) in 2004 to sunitinib (39.2%) and temsirolimus (15.2%) in 2009. Further, notable decreases were seen in the use of surgery and time-to-systemic treatment for patients with stage IV disease. Patients who were older, living in areas with lower educational attainment, and diagnosed in 2004 were significantly less likely to receive systemic therapy and had longer time-to-systemic treatment (P<.05). The findings indicate that over the past decade, treatment for RCC in the United States has evolved toward increased use of systemic therapy. As the diffusion of new therapies continues, it will be imperative to understand how variation in care for RCC will impact health outcomes and costs of care. (J Natl Compr Canc Netw 2014;12:1271-1279 In 2013, approximately 65,150 individuals in the United States were diagnosed with renal cell cancer (RCC).
In 2013, approximately 65,150 individuals in the United States were diagnosed with renal cell cancer (RCC). 1 Most (>60%) will have localized disease at diagnosis, although recurrences will develop in approximately 40% of patients initially treated for localized disease, and nearly 30% will be diagnosed with metastatic disease. 2 While surgery remains the primary treatment for localized RCC, 3 treatment options for metastatic RCC have changed markedly in the past decade. Before 2005, interferon alfa (IFN-α) and interleukin (IL)-2 comprised the available systemic treatment options. Since then, 7 new agents have been approved by the FDA for treatment of RCC: sorafenib, sunitinib, temsirolimus, bevacizumab, everolimus, pazopanib, and axitinib. 4, 5 In view of these developments, the current analysis of RCC treatment was conducted, building on a previous study in adults diagnosed with RCC. 6 Using a population-based sample of patients in the United States, the trends in treatment of RCC in community practice were examined, focusing on systemic therapy.
Patients and Methods

Data Source and Study Sample
NCI Patterns of Care Data:
The NCI SEER program collects information on all cancer diagnoses in defined geographic regions. Currently, SEER covers approximately 28% of the US population. 7 Information for each patient in SEER is primarily obtained from hospital records and includes tumor characteristics, treatment, and select demographic characteristics. Given that systemic therapies are primarily provided in outpatient settings, these data are underreported in SEER. To obtain therapy information that is not well-collected by routine SEER activities, NCI annually conducts Patterns of Care/Quality of Care studies on select cancer Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland. Submitted January 9, 2014; accepted for publication April 16, 2014 . This work was supported by National Cancer Institute contracts: HHSN261201000024C; HHSN261201000025C, HHSN261201000032C, HHSN261201000027C, HHSN261201000026C, HHSN261201000140C, HHSN261201000037C, HHSN261201000033C, HHSN261201000034C, HHSN261201000035C, HHSN261201000029C, HHSN261201000031C, HHSN261201000028C, and HHSN261201000030C. The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. This article is a US Government work and, as such, is in the public domain in the United States. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or NIH. 20 years were ineligible for the study. Eligible patients were stratified by registry, sex, race/ethnicity, and disease stage (2009 only), and randomly sampled within strata. Women, non-Hispanic blacks, Asian/ Pacific Islanders, Hispanics, American Indians, and Alaskan natives were oversampled to obtain more stable estimates for these groups. In 2009, patients with stage IV disease were oversampled. Sampling fractions were used to calculate weighted percentages that reflect the SEER populations from which the data were obtained.
Measures and Statistical Analyses
Patient characteristics included age at diagnosis, sex, race/ethnicity, marital status, insurance status, geographic region, and Census tract median household income and percent of individuals with less than a high school education. Clinical information included AJCC 6th edition tumor stage, tumor size, number of lymph nodes examined, number of positive lymph nodes, cell type, histologic grade, Charlson comorbidity score, primary site surgery, therapeutic agents, and clinical trial participation. Hospital characteristics included number of beds, ownership type, and residency training program.
Time-to-systemic treatment was defined as the number of days between (1) diagnosis and systemic therapy, for patients who did not receive cancer-directed surgery, and (2) surgery and systemic therapy, for patients who underwent surgery before receiving systemic therapy. Censoring events included date of last follow-up, date of death, or December 31, 2005 and December 31, 2010 (study cutoff dates for patients diagnosed in 2004 and 2009, respectively). Because SEER registries collect month and year of diagnosis, but not the day of diagnosis, the authors assumed that all patients were diagnosed on the first day of the month. The authors also assumed that all patients were followed through the last day of the month and, for all other events (date of surgery, date of systemic therapy), patients for whom data on the day of the event were missing, they assumed that patients experienced the event on the last day of the month (n=72). Cancer-directed surgery (eg, radical nephrectomy, complete/total/simple nephrectomy, partial/subtotal nephrectomy, or kidney resection with other organ resection) before systemic treatment, among patients who received systemic therapy, was categorized into a binary variable. Statistical Analyses: All descriptive information is presented as the total counts and weighted percentages. Patient, clinical, and hospital characteristics were compared, by year of diagnosis, using Pearson's chi-square test.
Evaluation of systemic therapy was conducted to assess the proportion of patients who received therapy within 12 months after diagnosis. Regression analysis was limited to patients with stage IV disease, for whom the NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer recommend systemic therapy (to view the most recent version of these guidelines, visit NCCN.org). 8 Among patients with stage IV disease who received systemic therapy, the authors measured (1) the type of systemic agent received and (2) the proportion of patients who received any surgery before systemic therapy treatment. Pearson's chi-square test was used to estimate differences between outcomes by year of diagnosis. In addition, logistic regression was used to evaluate the association between year of diagnosis and patient, clinical, and hospital characteristics and receipt of any systemic therapy within 12 months.
For time-to-systemic treatment analyses, Kaplan-Meier graphs were generated and Cox proportional hazards regression was used to assess the association between year of diagnosis and patient, clinical, and hospital characteristics and time-tosystemic treatment. The log-rank test was performed to test the equality of Kaplan-Meier failure curves by year of diagnosis. For the Cox regression analysis, a lower hazard ratio (HR; <1.0) reflects longer time to receipt of systemic therapy. Patients with missing information on month or year of systemic therapy were excluded from the time-to-treatment analysis only (n=84). Because the evaluation of time-to-systemic treatment reflects any changes in patterns of surgery between 2004 and 2009, sensitivity analyses were also conducted, wherein the authors stratified the time-to-systemic treatment analysis for patients who received surgery within 12 months postdiagnosis (n=290) and those did not receive surgery (n=348).
Patient, clinical, and hospital characteristics with a statistically significant association with the dependent variable at a P value less than .20 in bivariate analyses were retained in the multivariate regression models. Because of collinearity between Census tract estimates of median household income and percent of individuals with less than a high school education (correlation coefficient, 0.76), and a nonsignificant difference in median household income by year of diagnosis, the authors excluded income from the multivariate models. Charlson comorbidity score and SEER registry were included in all multivariate models. All tests of significance were 2-sided. Stata/SE 11.0 (StataCorp LP, College Station, TX) statistical software was used to incorporate sample weights in all analyses.
Results
Most patients, in both study years, were aged 50 to 69 years, married, had private insurance, and a Charlson comorbidity score of zero (Table 1) As shown in 
Discussion
Findings from this population-based study of patients with RCC in the United States highlight considerable changes in treatment patterns over time. Although previous studies have examined patterns of care among patients with RCC who received specific targeted therapies, 9-12 the authors believe theirs is the most comprehensive study examining systemic RCC treatment trends over time. They found a substantial increase in the use of systemic therapy for patients with stage IV RCC, from 35.7% in 2004 to 58.3% in 2009 (P<.001). Somewhat surprising, though, is the finding that nearly 40% of these patients did not receive any systemic therapy in 2009. However, it is possible that some of these stage IV patients started systemic treatment only after manifesting distant metastatic relapse, having nonmetastatic stage IV disease at diagnosis.
In the current study, sunitinib was the most commonly used systemic treatment for patients with stage IV RCC in 2009. This finding is consistent with that in a recent study by Hess et al 12 reporting that sunitinib was the most frequent first-line therapy among 273 patients with metastatic RCC. The present results indicate that use of both IL-2 and IFN decreased markedly between 2004 and 2009, each from approximately 16% to 2% of patients receiving systemic therapy. Toxicity profiles demonstrated clinical efficacy and ease of administration of the newer agents likely explain these trends. [13] [14] [15] Interestingly, formal FDA approval of IFN (in combination with bevacizumab) did not occur until 2009, although it has been used since the early 1990s in RCC treatment. 16 Of the 8 commonly used FDA-approved agents ( The present finding of a 34% decrease in the proportion of patients with stage IV RCC who underwent nephrectomy before receipt of systemic treatment between 2004 and 2009 extends the existing research [20] [21] [22] indicating a significant decline in the use of cytoreductive nephrectomy for patients with metastatic RCC after FDA approval of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI; eg, after 2005). This decreased use of surgery represents a change in the direction of the trend, because rates had been increasing in the years immediately following the results from 2 randomized controlled trials (SWOG 8949 and EORTC 30947) in 2001. [21] [22] [23] These 2 prospective randomized trials showed improved overall survival from cytoreductive nephrectomy in patients with metastatic RCC treated with IFN-α. 24, 25 Reluctance to subject patients to surgery given the availability of orally administered agents with proven clinical benefit may influence decision-making. There may also be reasonable doubts about the contribution of nephrectomy when combined with these novel systemic treatments. Two ongoing phase III randomized trials in Europe are evaluating the role of nephrectomy: CARMENA (ClinicalTrials.gov identifier: NCT00930033) is comparing sunitinib with or without nephrectomy, and SURTIME (EORTC-30073; ClinicalTrials.gov identifier: NCT01099423) is comparing sunitinib with immediate or deferred nephrectomy.
The significant decrease in time-to-systemic treatment within the first year after diagnosis for patients with stage IV RCC from 2004 to 2009 in the present study was likely influenced by many factors. Because patients undergoing a nephrectomy can start treatment only after adequate recovery from surgery, which would delay time to initiate systemic therapy, the authors accounted for receipt of surgery in their analysis. In addition, they conducted sensitivity analyses in which they found shorter times to systemic treatment in 2009 among patients treated with and without surgery. Patient age and educational attainment in the area of residence were found to influence the odds of receiving systemic therapy and time-to-systemic treatment. Saigal et al 26 reported similar findings of an inverse association between age at diagnosis and receipt of systemic therapy among patients with metastatic RCC. Although the current study controlled for the presence of comorbid conditions at diagnosis, the effect of age on both receipt of systemic therapy and time-to-systemic treatment is likely attributable to concerns about treatment tolerability. The authors' results of a positive association between education and receipt of systemic therapy add to findings from prior studies that suggest lower levels of educational attainment influence the treatment received by patients with cancer, [27] [28] [29] [30] which may be linked to several factors, including the availability and access to medical care. Moreover, among patients with advanced-stage disease, those presenting too late in the course of the disease, with poor performance status, may be considered poor candidates for treatment because of the possible side effects.
The results of the present study should be interpreted in the context of certain limitations. No data were available on the treating physician characteristics, including information on training and practice style, which has been shown to impact care deliv- ery. 31, 32 Further, information on patient preferences or experiences was not collected. These data were not mature enough for a reliable comparison of survival in 2004 to 2009. Although the authors controlled for several predictors of interest, some unmeasured factors may have influenced the treatment of patients with RCC. Finally, among patients with stage IV disease, data on the development of distant metastatic disease after initial treatment were not available.
Conclusions
The present findings indicate that treatment for RCC in the United States has evolved toward increased use of systemic therapy over the past decade. Availability of several novel systemic therapeutic agents has led to increased treatment options for patients with advanced RCC. As the diffusion of new therapies continues, understanding of how variation in care for RCC will impact health outcomes will be imperative, including therapeutic benefit, quality of life, and costs of care.
